Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.87%
- Poor long term growth as Net Sales has grown by an annual rate of 1.38% and Operating profit at -4.30% over the last 5 years
The company has declared Negative results for the last 3 consecutive quarters
Stock DNA
Pharmaceuticals & Biotechnology
INR 478 Cr (Micro Cap)
38.00
40
0.09%
0.60
5.92%
2.18
Total Returns (Price + Dividend) 
Latest dividend: 1.5 per share ex-dividend date: Sep-23-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 September 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 27 October 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.
Read More
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More Announcements 
Newspaper Publication (Financial Results)
12-Nov-2026 | Source : BSEEnclosed - Newspaper advertisement for Q2F27 (results)
Board Meeting Outcome for Meeting Held On November 11 2026
11-Nov-2026 | Source : BSEEnclosed - Outcome of 99th Board meeting.
Board Meeting Intimation for 99Th Board Meeting (11.11.2026)
07-Nov-2026 | Source : BSEHaleos Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 inter alia to consider and approve the unaudited financial results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30 2026 and any other item as may be decided by the Board of Directors.
Corporate Actions 
No Upcoming Board Meetings
Haleos Labs Limited has declared 15% dividend, ex-date: 23 Sep 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Annapurna Talluri (24.56%)
Harita Projects Private (1.76%)
24.1%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 12.30% vs 3.71% in Sep 2025
YoY Growth in quarter ended Sep 2026 is -46.56% vs 30.62% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -4.18% vs 6.83% in Sep 2024
Growth in half year ended Sep 2025 is -12.08% vs 1,141.96% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 1.19% vs 10.12% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -1.52% vs 438.99% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -3.17% vs 12.67% in Mar 2025
YoY Growth in year ended Mar 2026 is -13.92% vs 121.23% in Mar 2025